Our Portfolio

Megakaryon Corporation

Outline Development of platelet preparations using human induced pluripotent stem (hiPS) cells (It (1) can produce a stable supply of platelets, (2) has a high safety profile and (3) makes low-medical-cost blood transfusions possible)
Website

http://www.megakaryon.com/en/

Industry Health/medicine
Commercialization stage Early stage

Provided Support

  • In the field of regenerative medicine using iPS Cell, where Japan is at the forefront, Megakaryon is the leading start-up closest to world-wide commercialization
  • Artificially produced platelet preparations can overcome supply constraints and the risk of viral infection associated with dependence on donated blood
Authorized Investment ¥1 billion (maximum) / ¥2 billion (maximum) / ¥1.1 billion (maximum)
Announcement Date Aug 26, 2013 / Mar 23, 2015 / Dec 25, 2017
Investment Structure

Related Press Releases

Dec 25, 2017
INCJ to make additional investment in Megakaryon Corporation
Mar 23, 2015
INCJ to make additional investment in Megakaryon
HOME
About Us
Our Business
Newsroom
Our Investments